At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 39 enrolled
Drug / intervention
dasatinibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Study of Dasatinib in Advanced Melanoma
In Brief
A Phase 2 clinical trial evaluating dasatinib for Recurrent Melanoma and 4 related conditions. Completed, enrolled 39 participants across 2 sites.
Detailed Summary
This phase II trial is studying how well dasatinib works in treating patients with stage III melanoma that cannot be removed by surgery or stage IV melanoma. Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRecurrent Melanoma, Stage IIIA Melanoma, Stage IIIB Melanoma, Stage IIIC Melanoma, Stage IV Melanoma
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartDec 2006
First PostedFeb 2007
Primary CompletionMar 2010
Study CompletionNov 2010
TodayJul 2026
First PostedFeb 19, 2007
Enrollment StartDec 1, 2006
Primary CompletionMar 1, 2010
Study CompletionNov 1, 2010
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 19.4 years ago
Interventions
dasatinibdrug